Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia
COPD in 2025: Year in Review
FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector
Nephrology in 2025: Year in Review
1.
Simultaneously targeting lysosomal enzyme and KRAS-MAPK pathway eradicates pancreatic tumors in preclinical models
2.
Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows
3.
Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs
4.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
5.
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC
1.
Targeting the Tumor Microenvironment: Next-Generation Strategies for Immuno-Oncology Success
2.
Everything You Need to Know About CA 19-9 and Cancer Diagnosis
3.
Survival Rate Dynamics in Hematologic and Solid Malignancies
4.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
5.
Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XIV
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
3.
Navigating the Complexities of Ph Negative ALL - Part XIII
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge